<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table cellspacing="0" cellpadding="2" border="0" style="width: 100%" summary="This table shows the date, time, and location of the meeting" id="schedule"&gt;     &lt;tbody&gt;         &lt;tr&gt;             &lt;th width="10%" valign="top" bgcolor="#cccccc" align="left" id="a1"&gt;Center&lt;/th&gt;             &lt;th width="25%" valign="top" bgcolor="#cccccc" align="left" id="a2"&gt;Date&lt;/th&gt;             &lt;th width="25%" valign="top" bgcolor="#cccccc" align="left" id="a3"&gt;Time&lt;/th&gt;             &lt;th width="40%" valign="top" bgcolor="#cccccc" align="left" id="a4"&gt;Location&lt;/th&gt;         &lt;/tr&gt;         &lt;tr&gt;             &lt;td width="10%" valign="top" headers="a1"&gt;OC&lt;/td&gt;             &lt;td width="25%" valign="top" headers="a2"&gt;May 16, 2011&lt;/td&gt;             &lt;td width="25%" valign="top" headers="a3"&gt;8:00 a.m. - 3:00 p.m.&lt;/td&gt;             &lt;td width="40%" valign="top" headers="a4"&gt;Hilton Washington DC/Silver Spring&lt;br /&gt;               The Ballrooms&lt;br /&gt;               8727 Colesville Rd.&lt;br /&gt;               Silver Spring, MD&lt;br /&gt;           &amp;nbsp;&lt;/td&gt;         &lt;/tr&gt;     &lt;/tbody&gt; &lt;/table&gt; &lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;On May 16, 2011, the Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Public Law 107-109) and the Pediatric Research Equity Act (Public Law 110-85) for Bepreve (bepotastine besliate), Besivance (besifloxacin hydrochloride), Cetraxal (ciprofloxacin hydrochloride), Patanase Spray (olopatadine hydrochloride), Astepro Spray (azelastine hydrocholoride), Crestor (rosuvastatin calcium), Welchol (colesevelam hydrochloride), Intuniv (guanfacine), Lexapro (escitalopram oxalate), Actonel (risedronate), Hiberix [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)], and Valcyte (valganciclovir).  The committee will also receive further followup on Topical Calcineurin Inhibitors: Elidel (pimecrolimus) and Protopic (tacrolimus).&lt;/p&gt; &lt;p&gt;The Pediatric Advisory Committee will hear and discuss the recommendation of the Pediatric Ethics Subcommittee from its &lt;a href="[!--$wcmUrl('link','ucm251844.htm')--]" target=""&gt;meeting on May 11, 2011&lt;/a&gt;, regarding the Institutional Review Board process for clinical investigations that involve both an FDA regulated product and research involving children as subjects that is conducted or supported by HHS.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;&lt;strong&gt;Background material&lt;/strong&gt;     &lt;ul&gt;         &lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','ucm247489.htm')--]"&gt;2011 Meeting Materials, Pediatric Advisory Committee&lt;/a&gt;&lt;/li&gt;     &lt;/ul&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Public Participation and Sponsor Information&lt;/strong&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;Interested persons may present data,  information, or views, orally or in writing, on issues pending before the subcommittee.&lt;/p&gt; &lt;ul&gt;   &lt;li&gt;Written submissions may be made to the contact  person on or before May  2, 2011.&lt;/li&gt;     &lt;li&gt;Oral  presentations from the public will be scheduled between approximately 1 p.m.  and 2 p.m.&amp;nbsp; Those individuals interested  in making formal oral presentations should notify the contact person and submit  a brief statement of the general nature of the evidence or arguments they wish  to present, the names and addresses of proposed participants, and an indication  of the approximate time requested to make their presentation on or before April  25, 2011.&amp;nbsp;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Time  allotted for each presentation may be limited.&amp;nbsp;  If the number of registrants requesting to speak is greater than can be  reasonably accommodated during the scheduled open public hearing session, FDA  may conduct a lottery to determine the speakers for the scheduled open public  hearing session.&amp;nbsp; The contact person will  notify interested persons regarding their request to speak by April 26, 2011.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Walter Ellenberg, Ph.D.&lt;br /&gt; Office of Pediatric Therapeutics&lt;br /&gt; Office of the Commissioner&lt;br /&gt; Food and Drug Administration&lt;br /&gt; Bldg. 32, Room 5154&lt;br /&gt; 10903 New Hampshire Ave.&lt;br /&gt; Silver Spring, Maryland 20993-0002&lt;br /&gt; Phone: 301&amp;ndash;796-0885&lt;br /&gt; Fax: 301-847-8640&lt;br /&gt; E-mail: &lt;a href="mailto:walter.ellenberg@fda.hhs.gov"&gt;walter.ellenberg@fda.hhs.gov &lt;/a&gt;&lt;/p&gt; &lt;ul type="disc"&gt;     &lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;     1-800-741-8138&lt;br /&gt;     (301-443-0572 in the Washington DC area)&lt;br /&gt;     Code: 8732310001&lt;br /&gt;     Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt; &lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.&lt;/p&gt; &lt;p&gt;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Walter Ellenberg at (301) 796-0885 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings.&lt;/p&gt; &lt;p&gt;Please visit our Web site for &lt;a href="[!--$wcmUrl('link','ucm111462.htm')--]" target=""&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&amp;nbsp;&lt;/p&gt; &lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
